AstraZeneca Completes Acquisition of Amolyt Pharma

AstraZeneca has announced the successful completion of its acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The acquisition bolsters AstraZeneca's rare disease pipeline and expands its bone metabolism franchise with the addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide designed to treat hypoparathyroidism. This rare condition affects approximately 115,000 people in the United States and 107,000 in the European Union, predominantly women, and is characterized by a deficiency of parathyroid hormone, leading to significant dysregulation of calcium and phosphate levels.

Key Takeaways:

• AstraZeneca has acquired all of Amolyt Pharma's outstanding shares for a total consideration of up to $1.05 billion, including $800 million upfront and a potential additional contingent payment of $250 million.
• The acquisition expands AstraZeneca's late-stage pipeline and adds eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide designed to treat hypoparathyroidism, a rare condition affecting approximately 115,000 people in the United States and 107,000 in the European Union.
• Eneboparatide (AZP-3601) is designed to bind with high affinity to a specific conformation of the parathyroid hormone (PTH) receptor 1, regulating and maintaining serum calcium levels, and limiting urine calcium excretion.
• The acquisition brings AstraZeneca's total investment in rare endocrine diseases to over $1.05 billion, with the potential for additional growth through the achievement of regulatory milestones.
• AstraZeneca's rare disease pipeline is expected to benefit from Amolyt Pharma's talent, expertise, and earlier pipeline, enabling the company to expands its presence in rare endocrinology.
• Approximately 80% of people with hypoparathyroidism are women, and despite available treatments, patients experience persistent, life-altering symptoms and often develop complications and comorbidities.

Statistics:

• The acquisition of Amolyt Pharma is valued at up to $1.05 billion, including $800 million upfront and a potential additional contingent payment of $250 million.
• Approximately 115,000 people in the United States and 107,000 in the European Union are affected by hypoparathyroidism, a rare condition predominantly affecting women.
• Eneboparatide (AZP-3601) is a Phase III investigational therapeutic peptide designed to bind with high affinity to a specific conformation of the parathyroid hormone (PTH) receptor 1.

Sources:

• ENPublishing, "Astrazeneca - Acquisition of Amolyt Pharma completed" (July 16, 2024)
• AstraZeneca, "AstraZeneca Completes Acquisition of Amolyt Pharma" (July 16, 2024)